双重抗血小板治疗持续时间 - The Left Main and Coronary Artery Bifurcation Lesion Summit (CBS)

Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention
Rationale and design of a prospective substudy of clinical endpoint adjudication processes within an investigator-reported randomised controlled trial in patients with coronary artery disease: the GLOBAL LEADERS Adjudication Sub-StudY (GLASSY)
DAPT, Our Genome and Clopidogrel
A prospective, randomized, open-label trial of 6-month versus 12-month dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction: Rationale and design of the
Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial
Impact of bleeding during dual antiplatelet therapy in patients with coronary artery disease
Dual-Antiplatelet Therapy Cessation and Cardiovascular Risk in Relation to Age: Analysis From the PARIS Registry
Adjunctive Cilostazol to Dual Antiplatelet Therapy to Enhance Mobilization of Endothelial Progenitor Cell in Patients with Acute Myocardial Infarction: A Randomized, Placebo-Controlled EPISODE Trial
Ticagrelor With or Without Aspirin in High-Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention
A Prospective, Multicenter, Randomized, Open-label Trial to Compare Efficacy and Safety of Clopidogrel vs. Ticagrelor in Stabilized Patients with Acute Myocardial Infarction after Percutan eous Coronary Intervention: rationale and design of the TALOS-AMI trial

|<<... 4 5 6 7 8 9 10 >>|

Original Research

07 December 2020

JOURNAL：Sci Rep.

Article Link

Impact of bleeding during dual antiplatelet therapy in patients with coronary artery disease

Y-C Tung, C-T Kuo, C-J Chang et al.

4202

Keywords: bleeding risk; DAPT; CAD

Full Text PDF

网站资料更新中...